Exact Sciences
Interim Data From Mainz Biomed Study Boosts Profile of Next-Generation Colorectal Cancer Test
Premium
The interim results found the ColoAlert test had a sensitivity of 94 percent and specificity of 97 percent, with sensitivity for advanced adenoma of 80 percent.
Exact Sciences Sues Geneoscopy, Alleging Patent Infringement
Exact Sciences claims that Geneoscopy's ColoSense colorectal cancer screening assay infringes upon a patent covering Exact's Cologuard assay.
The company's data, presented at a recent meeting and simultaneously published, showed performance results analogous to currently marketed tests.
The company recently shared positive results from its Blue-C study, intended to support an FDA approval bid for a second generation of its colon cancer screening test.
Genomic Health to Pay $32.5M to Resolve Cancer Test False Claims Allegations by DOJ
The settlement includes the resolution of allegations brought in two separate actions filed against the firm under the whistleblower provisions of the False Claims Act.